trending Market Intelligence /marketintelligence/en/news-insights/trending/kGEYUU2ss7QifMKFuXc_FQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Edwards Lifesciences profit beats consensus by 15.6% in Q3

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Edwards Lifesciences profit beats consensus by 15.6% in Q3

Edwards Lifesciences Corp. said its third-quarter adjusted earnings amounted to $1.41 per share, compared with the S&P Global Market Intelligence consensus normalized EPS estimate of $1.22 per share.

EPS climbed 31.8% year over year from $1.07.

Adjusted earnings totaled $299.2 million, a gain of 31.2% from $228.1 million in the year-earlier period. Net sales grew 20.7% year over year to $1.09 billion from $906.6 million.

GAAP net income increased 21.6% year over year to $274.7 million, or $1.30 per share, from $225.9 million, or $1.06 per share.

The Irvine, Calif.-based medical-device maker forecasts adjusted EPS in the range of $5.50 to $5.65 for the full year 2019, an increase from previous guidance in the range of $5.20 to $5.40.

Edwards Lifesciences expects total sales in the range of $4 billion to $4.3 billion for the full year.